Bowen Disease



First described by the American dermatologist John T. Bowen in 1912, Bowen disease is a squamous cell carcinoma (SCC) in situ with the potential for significant lateral spread.[1] Larger lesions can reach several centimeters in diameter.

The image below depicts Bowen disease of the right temple.

View Image

Bowen disease right temple.

See Nonmelanoma Skin Cancers You Need to Know, a Critical Images slideshow, to help correctly identify these lesions.


Bowen disease is a form of intraepidermal carcinoma, a malignant tumor of keratinocytes. Bowen disease may ultimately progress to an invasive squamous cell carcinoma.


Bowen disease may arise de novo or from a preexisting actinic keratosis. The etiology is most likely multifactorial.Note the following:

Other possible causes include genetic factors, trauma, other chemical carcinogens, and x-ray radiation.


US frequency

Because no national health databases collect the numbers of nonmelanoma skin cancers and because of regional differences in incidence rates, estimating the frequency of Bowen disease is difficult. In 1991, a study from Minnesota reported the annual average rate of Bowen disease as 14.9 cases per 100,000 whites.[10] In 1994, a study from Hawaii reported a rate 10 times that, 142 cases per 100,000 whites.[11]


Bowen disease is most commonly reported in sun-exposed sites of whites. Bowen disease rarely occurs in patients with darker-pigmented skin; if it does, it usually affects nonexposed sites.[12]


The ratio of Bowen disease is approximately equal between males and females. Bowen disease is more commonly found on the head and neck of men and on the lower limbs and cheeks of women.[2]


Bowen disease occurs in adulthood, with the highest incidence in patients older than 60 years.[13]


The prognosis for Bowen disease is favorable. The majority of studies report a risk of progression to invasive SCC at 3-5%. According to a retrospective case series with multiple potential biases, of those that become invasive SCC, one third may metastasize. The risk of invasive carcinoma is estimated to be higher for genital Bowen disease or erythroplasia of Queyrat at 10%.[14]

Much controversy surrounds whether Bowen disease is associated with internal malignancies.[15, 16, 17, 18, 19] Many early papers reported such an association in 15-70% of cases. Some later reports supported an association of internal malignancies with Bowen disease that was associated with arsenic ingestion but not with Bowen disease from other causes.[3] In 1989, a meta-analysis of 12 studies showed no significant association. The most recent population-based cohort study of 1147 Bowen disease patients in Denmark demonstrated no statistically significant increased risk of internal cancers. Currently, Bowen disease is not believed to be a paraneoplastic condition.[19]

Patient Education

Patients with a history of Bowen disease should be counseled on safe sun behavior, to include avoiding the sun when it is most intense (between 10 am and 4 pm), wearing hats and other sun protective clothing, and using a dual-spectrum sunscreen with an SPF of 30 or higher.

For patient education resources, visit the Cancer Center and First Aid and Injuries Center. Also, see the patient education articles Skin Cancer, Skin Biopsy, and Sunburn.


Patients often present with an asymptomatic, slowly enlarging, erythematous, well-demarcated scaly patch or plaque. It may occur anywhere on the mucocutaneous surface. A delay in diagnosis of Bowen disease often is encountered because the lesion is asymptomatic; early skin changes may be subtle and overlap with clinical features seen in many conditions, such as tinea corporis, nummular eczema, seborrheic keratosis,[20, 21] Paget disease, superficial basal cell carcinoma, actinic keratosis, and psoriasis. A classic clinical history is presentation of a non–steroid-responsive dermatosis.

Physical Examination

Bowen disease presents as a single lesion in two thirds of cases. Lesions may appear on sun-exposed or covered skin. The head, neck, and extremities are the most commonly affected anatomic locations in men, while the lower limbs and cheeks are most commonly affected in women.[22] Lesions, as shown in the images below, vary in size from a few millimeters to several centimeters in diameter.

View Image

Squamous cell carcinoma in situ, Bowen disease. Courtesy of Hon Pak, MD.

View Image

Bowen disease right temple.

A sharply demarcated, irregular border usually is present. Lesions are erythematous, scaly patches or plaques that may become hyperkeratotic, crusted, fissured, or ulcerated. Rarely, the lesions are pigmented, especially in the genital region and the nails.[23] Lesions in these locations may simulate melanoma.[24] Bowen disease also may occur on mucous membranes. When it arises on the glans penis, it is referred to as erythroplasia of Queyrat and presents as an erythematous, moist, velvety or smooth plaque, as demonstrated in the image below.

View Image

Erythroplasia of Queyrat, squamous cell carcinoma in situ of the glans penis.


Skin biopsy

Perform a shave or punch biopsy to confirm the diagnosis of Bowen disease. Incorporating follicular structures in the biopsy material is helpful, as is sampling many areas of larger lesions to exclude evidence of invasion amounting to a cutaneous squamous cell carcinoma. These procedures are typically performed in an office setting with the patient under local anesthesia. Pathologic analyses are best completed by dermatopathologists.

Complete skin examination

Perform a total body skin examination on patients with Bowen disease on sun-exposed skin. Studies indicate a higher incidence of nonmelanoma skin cancers may exist in these patients.

Histologic Findings

Bowen disease is a full-thickness anaplasia of the epidermis, with loss of the normal maturation of its components. Keratinocytes are atypical and disorderly, often described as having a windblown appearance. Although the basal cell layer is intact, extension of keratinocyte atypia down the follicular epithelium is seen. Vacuolization, mitoses, individually keratinizing cells, and multinucleated cells are present in the epidermis. Large pale keratinocytes with abundant ground-glass cytoplasm, so-called pagetoid cells, often are distributed haphazardly throughout the epidermis. Hyperkeratosis, parakeratosis, and acanthosis are seen to some degree in lesions of Bowen disease. The upper dermis has a moderate lymphocytic infiltrate.

Neoplastic cells tend to crowd the adnexal structures. The histological and nested pattern can appear similar to clonal seborrheic keratosis.[25] They can be distinguished by negative cytokeratin 10 immunohistochemical staining in nests of atypical cells found in seborrheic keratosis.[26] Tumor cells in Bowen disease typically stain positive for p53, HPV, and high molecular weight cytokeratin (which includes cytokeratin 10).[27, 28]

Genetically, an increased expression and mutation of TP53 has been observed. In addition, lesions have been reported to have one or more deletions in the 9q markers.

Medical Care

For specific guidelines and recommendations, please see “British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma in situ (Bowen’s disease) 2014.”[14] These were determined by the British Association of Dermatologists in 2014.

Each treatment modality has advantages and disadvantages. Choosing the best therapeutic option involves an analysis of various factors such as lesional size, number, site, degree of functional impairment, modality availability, and cost. Because most treatments have a recurrence risk, follow-up at 6-12 months is recommended to evaluate for recurrence. Factors that dictate a shorter follow-up period include history of past recurrence, presence of multiple lesions, lesions in high-risk locations, and immunosuppression.

5-Fluorouracil is a topical antineoplastic agent that interferes with DNA synthesis via inhibition of thymidylate synthetase and subsequently cell proliferation. It is used clinically as a 5% cream once or twice daily for a variable period, ranging from 1 week to 3 months. 5-Fluorouracil has also been applied under occlusion, with dinitrochlorobenzene as a vehicle, via iontophoresis or pretreatment with an Er:YAG laser. The main advantage is easy self-application by patients. The main adverse effect is irritation with erosions and ulcerations that may last several weeks.[29, 30, 31, 32] A disadvantage is that it may not be able to penetrate deep enough to treat any deep follicular extension of the tumor cells.

Imiquimod 5% cream,[33, 34, 35, 36] a topical immune response modifier, applied 3-7 d/wk, appears to possibly be a successful treatment option for Bowen disease. It is often used for larger-diameter lesions, lower leg lesions, and erythroplasia of Queyrat. Two reports indicate sustained clearance with at least 19 months of disease-free follow-up after treatment of perianal Bowen disease with single-agent therapy using imiquimod 5% cream. Topical treatment for perianal Bowen disease may minimize the risk of scarring, poor wound healing, and functional impairment. The ideal dosing regimen is still under investigation, but the most studied regimen at this time is imiquimod 5% cream once daily for 16 weeks. Also note, however, that a cautionary report describes Bowen disease of the scalp treated with imiquimod that evolved into invasive SCC.[37]

Consider x-ray or grenz-ray radiation therapy for poor surgical candidates or patients with multiple lesions.[38, 39] It should be avoided for lower extremity lesions due to impaired healing.

Photodynamic therapy (PDT) has also been used, with variable success, for the treatment of Bowen disease.[40, 41] Photodynamic therapy involves the introduction of a photosensitizing agent into the body, which is retained preferentially by the tumor cells. Then, a light source is used to stimulate the photosensitizing agent, causing the release of toxins and leading to the destruction of the tumor. Topical 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) are the most commonly used photosensitizers. Various illumination sources, wavelengths of light, and dosing schedules have been used. PDT is well-suited for large lesions, multiple lesions, and poor-healing sites.[42] The adverse effects include local phototoxic effects such as burning and stinging and, rarely, erosions, ulceration, and hyperpigmentation hypopigmentation. Treatment guidelines are available from the Norwegian University of Science and Technology.[43]

Surgical Care

Simple excision with conventional margins

This surgery is the most common and preferred treatment for smaller lesions and those not in problematic areas, such as the face and digits.[44] For perianal Bowen disease, excision with wide margin is recommended.[45] Lower leg lesions are often limited by the lack of skin mobility.

Although lesions are typically well demarcated, the actual extent of the disease may be well beyond the clinical margins. For this reason, the excision should be made at least 4 mm outside the clinical margin.

Mohs micrographic surgery [46]

This is an excellent method for larger lesions, poorly demarcated lesions, recurrent lesions on the head and neck, or areas where tissue sparing is vital, such as digital or genital lesions. Mohs micrographic surgery uses the systematic surgical removal of skin cancers with very small margins of normal tissue followed by frozen section examination of nearly 100% of the tissue margin.

It offers the highest cure rate of all treatment modalities, and, because relatively thin layers are taken only in areas of proven tumor, it is a tissue-sparing procedure.

Curettage and electrodesiccation, cryotherapy, and laser ablation [47, 48, 49]

These are blind surgical methods (no pathologic confirmation of removal) that are established treatment modalities for Bowen disease.

As compared with excision and Mohs surgery, they are less likely to remove tumors that are present down adnexal structures.

Curettage and electrodesiccation is a common and safe modality. Treatment efficacy is largely determined by the skill of the clinician. It is also one of the most cost-effective treatment modalities.

Cryotherapy is another common therapeutic option, especially for single and small lesions. Suggested regimens in the literature include a single 30-second freeze-thaw cycle, 2 freeze-thaw cycles of 20 seconds with a thaw period, or up to 3 single treatments of 20 seconds at intervals of several weeks. The risk of poor wound healing (eg, hypopigmented scarring) increase with prolonged freezing times. Treatment of broad lesions is often limited because of patient discomfort.

Case reports and series have shown a benefit of using argon, carbon dioxide, and Nd:YAG lasers in the treatment of some Bowen disease lesions.


Counsel at-risk individuals in the use of sunscreens, photoprotective clothing, and other measures to minimize further actinic damage. Frequent and routine screening should also be stressed to these patients.

Long-Term Monitoring

Patients with a history of any type of skin cancer should be evaluated with a total body skin examination every 6-12 months.

One study demonstrated the use of dermatoscopy when following Bowen disease. The visualization of vascular structures corresponded with incomplete treatment of disease or recurrence of disease. An absence of vascular structures corresponded with a complete remission.[50]

Medication Summary

The goals of therapy for Bowen disease are to reduce morbidity and to prevent complications.

5-Fluorouracil (Efudex, Carac, Adrucil, Fluoroplex)

Clinical Context:  5-Fluorouracil administered topically under occlusion, following the use of keratolytic or cryotherapy, or by iontophoresis (an electrogradient-driven chemical delivery system), can be used. It interferes with DNA synthesis by blocking methylation of deoxyuridylic acid and inhibits thymidylate synthetase, which subsequently reduces cell proliferation.

Imiquimod (Aldara)

Clinical Context:  The precise mechanism of action for the treatment of Bowen disease is unknown. It may increase tumor infiltration of lymphocytes, dendritic cells, and macrophages. It is indicated when surgical methods are not appropriate.

Class Summary

These are topical agents that may be used in the management of Bowen disease.


Mary V Kaldas, MD, Resident Physician in Anatomic Pathology, National Institutes of Health

Disclosure: Nothing to disclose.


Mark P Eid, MD, Founder and Director, Virginia Dermatology and Skin Surgery Center

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Bryan E Anderson, MD, Associate Professor, Department of Dermatology, Pennsylvania State University College of Medicine

Disclosure: Nothing to disclose.

Kelly M Cordoro, MD, Assistant Professor of Clinical Dermatology and Pediatrics, Department of Dermatology, University of California, San Francisco School of Medicine

Disclosure: Nothing to disclose.


Theresa Dressler Conologue, DO, FAAD Physician, Department of Dermatology, Geisinger Medical Center

Disclosure: Nothing to disclose.

Carrie A H Hall, MD Resident Physician, National Capital Consortium Dermatology Residency Program, National Naval Medical Center

Disclosure: Nothing to disclose.

Mark L Welch, MD Clinical Assistant Professor, Department of Dermatology, Howard University; Assistant Professor, Department of Dermatology, Uniformed Services University of the Health Sciences

Disclosure: Nothing to disclose.


  1. Zhan W, Liao X, Tian T, Zhang RY, Li P, Wu XP, et al. Perianal multiple Bowen's disease: a case report. Int J Clin Exp Pathol. 2015. 8 (11):15039-41. [View Abstract]
  2. Kossard S, Rosen R. Cutaneous Bowen's disease. An analysis of 1001 cases according to age, sex, and site. J Am Acad Dermatol. 1992 Sep. 27(3):406-10. [View Abstract]
  3. Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum Toxicol. 1989 Mar. 8(2):99-104. [View Abstract]
  4. Hunt KM, Srivastava RK, Elmets CA, Athar M. The mechanistic basis of arsenicosis: Pathogenesis of skin cancer. Cancer Lett. 2014 Aug 27. [View Abstract]
  5. Derancourt C, Mougin C, Chopard Lallier M, Coumes-Marquet S, Drobacheff C, Laurent R. [Oncogenic human papillomaviruses in extra-genital Bowen disease revealed by in situ hybridization]. Ann Dermatol Venereol. 2001 Jun-Jul. 128(6-7):715-8. [View Abstract]
  6. McKee P, Calonje E, Granter S. Tumors of the surface epithelium. Pathology of the Skin. 3rd. London: Elsevier Mosby; 2005. 2: 1193-1197.
  7. Shim WH, Park HJ, Kim HS, et al. Bowenoid Papulosis of the Vulva and Subsequent Periungual Bowen's Disease Induced by the Same Mucosal HPVs. Ann Dermatol. 2011 Nov. 23(4):493-6. [View Abstract]
  8. Euvrard S, Chardonnet Y, Pouteil-Noble C, et al. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients. Cancer. 1993 Oct 1. 72(7):2198-206. [View Abstract]
  9. Drake AL, Walling HW. Variations in presentation of squamous cell carcinoma in situ (Bowen's disease) in immunocompromised patients. J Am Acad Dermatol. 2008 Jul. 59(1):68-71. [View Abstract]
  10. Chute CG, Chuang TY, Bergstralh EJ, Su WP. The subsequent risk of internal cancer with Bowen's disease. A population-based study. JAMA. 1991 Aug 14. 266(6):816-9. [View Abstract]
  11. Reizner GT, Chuang TY, Elpern DJ, Stone JL, Farmer ER. Bowen's disease (squamous cell carcinoma in situ) in Kauai, Hawaii. A population-based incidence report. J Am Acad Dermatol. 1994 Oct. 31(4):596-600. [View Abstract]
  12. Gupta S, Nutan, Dogra S, Kanwar AJ. Bowen Disease over photoprotected site in an Indian male. Dermatol Online J. 2009 Oct 15. 15(10):16. [View Abstract]
  13. Kovacs A, Yonemoto K, Katsuoka K, Nishiyama S, Harhai I. Bowen's disease: statistical study of a 10 year period. J Dermatol. 1996 Apr. 23(4):267-74. [View Abstract]
  14. [Guideline] Morton CA, Birnie AJ, Eedy DJ. British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014. Br J Dermatol. 2014 Feb. 170(2):245-60. [View Abstract]
  15. Arbesman H, Ransohoff DF. Is Bowen's disease a predictor for the development of internal malignancy? A methodological critique of the literature. JAMA. 1987 Jan 23-30. 257(4):516-8. [View Abstract]
  16. Graham JH, Helwig EB. Bowen's disease and its relationship to systemic cancer. AMA Arch Derm. 1959 Aug. 80(2):133-59. [View Abstract]
  17. Jaeger AB, Gramkow A, Hjalgrim H, Melbye M, Frisch M. Bowen disease and risk of subsequent malignant neoplasms: a population-based cohort study of 1147 patients. Arch Dermatol. 1999 Jul. 135(7):790-3. [View Abstract]
  18. Poole S, Fenske NA. Cutaneous markers of internal malignancy. II. Paraneoplastic dermatoses and environmental carcinogens. J Am Acad Dermatol. 1993 Feb. 28(2 Pt 1):147-64. [View Abstract]
  19. Jaeger AB, Gramkow A, Hjalgrim H, Melbye M, Frisch M. Bowen disease and risk of subsequent malignant neoplasms: a population-based cohort study of 1147 patients. Arch Dermatol. 1999 Jul. 135(7):790-3. [View Abstract]
  20. Boer-Auer A, Jones M, Lyasnichaya OV. Cytokeratin 10-negative nested pattern enables sure distinction of clonal seborrheic keratosis from pagetoid Bowen's disease. J Cutan Pathol. 2012 Feb. 39(2):225-33. [View Abstract]
  21. Terada T. Pigmented Bowen disease arising in pigmented reticulated seborrheic keratosis. Int J Clin Oncol. 2010 Dec. 15(6):608-10. [View Abstract]
  22. Jung SE, Kim SK, Kim YC. Photodynamic therapy in Bowen disease of the first web space of the hand. Ann Dermatol. 2015 Feb. 27 (1):76-8. [View Abstract]
  23. Perruchoud DL, Varonier C, Haneke E, Hunger RE, Beltraminelli H, Borradori L, et al. Bowen disease of the nail unit: a retrospective study of 12 cases and their association with human papillomaviruses. J Eur Acad Dermatol Venereol. 2016 Sep. 30 (9):1503-6. [View Abstract]
  24. Saxena A, Kasper DA, Campanelli CD, Lee JB, Humphreys TR, Webster GF. Pigmented Bowen's disease clinically mimicking melanoma of the nail. Dermatol Surg. 2006 Dec. 32(12):1522-5. [View Abstract]
  25. Kalegowda IY, Böer-Auer A. Clonal Seborrheic Keratosis Versus Pagetoid Bowen Disease: Histopathology and Role of Adjunctive Markers. Am J Dermatopathol. 2017 Jun. 39 (6):433-439. [View Abstract]
  26. Boer-Auer A, Jones M, Lyasnichaya OV. Cytokeratin 10-negative nested pattern enables sure distinction of clonal seborrheic keratosis from pagetoid Bowen's disease. J Cutan Pathol. 2012 Feb. 39(2):225-33. [View Abstract]
  27. Fernandez-Flores A. Cytokeratin 17 immunoexpression in actinic keratosis (bowenoid and nonbowenoid) and in Bowen disease. Ann Diagn Pathol. 2016 Feb. 20:1-6. [View Abstract]
  28. Idriss MH, Misri R, Böer-Auer A. Orthokeratotic Bowen disease: a histopathologic, immunohistochemical and molecular study. J Cutan Pathol. 2016 Jan. 43 (1):24-31. [View Abstract]
  29. Bargman H, Hochman J. Topical treatment of Bowen's disease with 5-Fluorouracil. J Cutan Med Surg. 2003 Mar-Apr. 7(2):101-5. [View Abstract]
  30. Fulton JE Jr, Carter DM, Hurley HJ. Treatment of Bowen's disease with topical 5-fluorouracil under occlusion. Arch Dermatol. 1968 Feb. 97(2):178-80. [View Abstract]
  31. Sturm HM. Bowen's disease and 5-fluorouracil. J Am Acad Dermatol. 1979 Dec. 1(6):513-22. [View Abstract]
  32. Welch ML, Grabski WJ, McCollough ML, et al. 5-fluorouracil iontophoretic therapy for Bowen's disease. J Am Acad Dermatol. 1997 Jun. 36(6 Pt 1):956-8. [View Abstract]
  33. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001 Mar. 44(3):462-70. [View Abstract]
  34. van Egmond S, Hoedemaker C, Sinclair R. Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol. 2007 Mar. 46(3):318-9. [View Abstract]
  35. Alessi SS, Sanches JA, de Oliveira WR, Messina MC, Pimentel ER, Festa Neto C. Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo). 2009. 64(10):961-6. [View Abstract]
  36. Imiquimod for superficial and in situ skin malignancy. Drug Ther Bull. 2009 Oct. 47(10):113-6. [View Abstract]
  37. Fernandez-Vozmediano J, Armario-Hita J. Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod cream. J Am Acad Dermatol. 2005 Apr. 52(4):716-7. [View Abstract]
  38. Dupree MT, Kiteley RA, Weismantle K, Panos R, Johnstone PA. Radiation therapy for Bowen's disease: lessons for lesions of the lower extremity. J Am Acad Dermatol. 2001 Sep. 45(3):401-4. [View Abstract]
  39. Anna Z, John K, Maria T, et al. The potential role of radiation therapy in Bowen's disease: a review of the current literature. Rev Recent Clin Trials. 2012 Feb. 7(1):42-6. [View Abstract]
  40. [Guideline] Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007 Jan. 56(1):125-43. [View Abstract]
  41. Jones CM, Mang T, Cooper M, Wilson BD, Stoll HL Jr. Photodynamic therapy in the treatment of Bowen's disease. J Am Acad Dermatol. 1992 Dec. 27(6 Pt 1):979-82. [View Abstract]
  42. O'Connell KA, Okhovat JP, Zeitouni NC. Photodynamic therapy for Bowen's Disease (squamous cell carcinoma in situ) current review and update. Photodiagnosis Photodyn Ther. 2018 Dec. 24:109-114. [View Abstract]
  43. [Guideline] Christensen E, Warloe T, Kroon S, et al. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2010 May. 24 (5):505-12. [View Abstract]
  44. Ferrandiz L, Ruiz-de-Casas A, Trakatelli M, et al. Assessing physicians' preferences on skin cancer treatment in Europe. Br J Dermatol. 2012 Aug. 167 Suppl 2:29-35. [View Abstract]
  45. Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Treatment options for perianal Bowen's disease: survery of American Society of Colon and Rectal Surgeons Members. Am Surg. 2000 Jul. 66(7):686-8. [View Abstract]
  46. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005 Jun. 52(6):997-1002. [View Abstract]
  47. Tantikun N. Treatment of Bowen's disease of the digit with carbon dioxide laser. J Am Acad Dermatol. 2000 Dec. 43(6):1080-3. [View Abstract]
  48. Neubert T, Lehmann P. Bowen's disease - a review of newer treatment options. Ther Clin Risk Manag. 2008 Oct. 4(5):1085-95. [View Abstract]
  49. Moreno G, Chia AL, Lim A, Shumack S. Therapeutic options for Bowen's disease. Australas J Dermatol. 2007 Feb. 48(1):1-8; quiz 9-10. [View Abstract]
  50. Mun JH, Park JM, Song M, et al. The use of dermatoscopy to monitor therapeutic response of Bowen disease: a dermatoscopic pathological study. Br J Dermatol. 2012 Dec. 167(6):1382-5. [View Abstract]
  51. Arnold HL, Odom RB, James WD. Bowen's disease. Arnold HL, Andrews GC, Odom RB, James WB, eds. Andrews' Diseases of the Skin. 8th ed. Philadelphia, Pa: WB Saunders; 1990. 783-5.

Bowen disease right temple.

Squamous cell carcinoma in situ, Bowen disease. Courtesy of Hon Pak, MD.

Bowen disease right temple.

Erythroplasia of Queyrat, squamous cell carcinoma in situ of the glans penis.

Squamous cell carcinoma in situ, Bowen disease. Courtesy of Hon Pak, MD.

Bowen disease right temple.

Erythroplasia of Queyrat, squamous cell carcinoma in situ of the glans penis.